AgiBot has launched LinkCraft, the world’s first zero-code robot content creation platform for effortless humanoid robot ...

Harmony Biosciences’ $60 million bet on a once-failed Fragile X candidate has gone off the rails. Two years after picking up ZYN002 despite a midphase flop, the biotech has reported that a ...

Harmony Biosciences Holdings, Inc. is downgraded from Buy to Hold after a failed Phase 3 trial for ZYN002 in Fragile X syndrome. HRMY's pipeline setback and sNDA rejection raise concerns about ...